NasdaqGM - Nasdaq Real Time Price USD

Acrivon Therapeutics, Inc. (ACRV)

1.6100 +0.0400 (+2.55%)

At close: November 6 at 4:00:01 PM EST

1.6300 +0.0200 (+1.24%)

After hours: November 6 at 5:50:49 PM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB

GlobeNewswire 2d ago

ACRV
+3.82%
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire 4d ago

ACRV
+3.82%
Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium

GlobeNewswire 10d ago

ACRV
+3.82%
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

GlobeNewswire 19d ago

ACRV
+3.82%
What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock

Zacks 1mo ago

ACRV
+3.82%
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?

Zacks 2mo ago

ACRV
+3.82%
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

GlobeNewswire 2mo ago

ACRV
+3.82%
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

GlobeNewswire 2mo ago

ACRV
+3.82%
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy

Zacks 2mo ago

ACRV
+3.82%
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

GlobeNewswire 3mo ago

ACRV
+3.82%
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

GlobeNewswire 5mo ago

ACRV
+3.82%
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 5mo ago

ACRV
+3.82%

Performance Overview

Return	ACRV	S&P 500 (^GSPC)
YTD	-33.20%	+7.76%
1-Year	-19.50%	+9.77%
3-Year	-71.65%	+68.96%

U.S. markets closed

Acrivon Therapeutics, Inc. (ACRV)

Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB

Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock

Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)